Recently, Christenbury et al. described a high level of macular atrophy development predominantly eccentric to the PED in long-term anti-VEGF therapy for eyes with type 1 NV secondary to AMD [13]. The gene discussed is VEGFA; the disease is age-related macular degeneration.